46,972 Shares in Theravance Biopharma, Inc. $TBPH Bought by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC has acquired 46,972 shares of Theravance Biopharma, Inc., valued at around $419,000, making it a new investor in the company as reported in their recent SEC filing.
• Multiple hedge funds, including Northern Trust Corp and Bank of America Corp DE, have increased their stakes in Theravance Biopharma, indicating a strong interest from institutional investors, who now hold 99.1% of the company's stock.
• Equities analysts have raised Theravance Biopharma's rating to "strong-buy", with a consensus target price of $21.33, reflecting positive market sentiment towards the company's future performance.

Cubist Systematic Strategies LLC bought a new position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 46,972 shares of the biopharmaceutical company's stock, valued at approximately $419,000. Cubist Systematic Strategies LLC owned about 0.09% of Theravance Biopharma at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Northern Trust Corp raised its stake in shares of Theravance Biopharma by 1.6% during the 4th quarter. Northern Trust Corp now owns 389,980 shares of the biopharmaceutical company's stock valued at $3,670,000 after buying an additional 6,198 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Theravance Biopharma by 2.7% in the 4th quarter. Bank of America Corp DE now owns 481,475 shares of the biopharmaceutical company's stock valued at $4,531,000 after buying an additional 12,596 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in shares of Theravance Biopharma by 9.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company's stock valued at $7,847,000 after buying an additional 69,178 shares during the period. Deutsche Bank AG lifted its holdings in shares of Theravance Biopharma by 50.4% in the 4th quarter. Deutsche Bank AG now owns 46,550 shares of the biopharmaceutical company's stock valued at $438,000 after buying an additional 15,608 shares during the period. Finally, Graham Capital Management L.P. lifted its holdings in shares of Theravance Biopharma by 18.2% in the 4th quarter. Graham Capital Management L.P. now owns 36,364 shares of the biopharmaceutical company's stock valued at $342,000 after buying an additional 5,608 shares during the period. Hedge funds and other institutional investors own 99.10% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 16th. Zacks Research raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Friday, August 15th. BTIG Research boosted their price objective on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a report on Friday, June 27th. Finally, Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target for the company in a research note on Tuesday, June 17th. Two investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat.com, Theravance Biopharma has a consensus rating of "Strong Buy" and a consensus target price of $21.33.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the transaction, the senior vice president directly owned 326,918 shares in the company, valued at $3,723,596.02. The trade was a 2.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Trading Down 0.9%

NASDAQ:TBPH opened at $13.64 on Thursday. Theravance Biopharma, Inc. has a 12 month low of $7.88 and a 12 month high of $14.55. The stock has a 50 day moving average of $12.28 and a two-hundred day moving average of $10.52. The firm has a market cap of $686.91 million, a P/E ratio of 56.83 and a beta of 0.05.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.